Chair and Chief Executive, Amgen Inc.
Bradway joined biotech giant Amgen in 2006, becoming chief executive in 2012 and chair a year later. The company has a market cap of more than $120 billion – making it the second largest public company in the Los Angeles area. It recently shed more than 700 workers, which it attributed to pressure on drug prices and high inflation. In recent years, Bradway has honed Amgen’s focus on drugs to treat cancers as well as cardiovascular and inflammatory diseases. Prior to joining Amgen, Bradway spent 20 years at Morgan Stanley, rising through the ranks to become managing director at the finance firm’s London office. Bradway is also a director of Boeing Co. and chairs its finance committee.